Clinical trials: Bladder, Overactive
Overactive Bladder
Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)
The purpose of this study is to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).
- Trial name
- VECTOR (NCT00431041)
- Testing
- solifenacin, oxybutynin immediate release
- Where
- 12 sites in Canada
- Volunteers
- 132 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder
A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients
The purpose of this study was to evaluate the safety and efficacy of mirabegron as add-on therapy in patients with OAB treated with solifenacin.
- Trial name
- NCT01745094
- Testing
- mirabegron, solifenacin
- Where
- 5 sites in Japan
- Volunteers
- 223 people
- Sponsor
- Astellas Pharma Inc
Urinary Bladder, Overactive
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
The study is intended to test efficacy, safety and tolerability of two doses of Mirabegron against placebo and compare the efficacy and safety with active comparator in patients with symptoms of overactive bladder.
- Trial name
- SCORPIO (NCT00689104)
- Testing
- Mirabegron, Tolterodine
- Where
- 218 sites in Australia, Austria and 28 more
- Volunteers
- 2,336 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder
Fall Prevention in Older Adults With OAB
Though OAB treatment may improve physical activity, there is a lack of easily administered instruments for measuring physical activity in older adults.
- Trial name
- NCT03946124
- Testing
- Fesoterodine
- Volunteers
- 74 people
- Sponsor
- University of Pennsylvania
Overactive Bladder, Urinary Incontinence
Percutaneous Nerve Evaluation With Fluoroscopy Versus Without
The investigators propose a randomized control trial comparing the rate of implantation of the InterStim device following Percutaneous Nerve Evaluation (PNE) performed with or without fluoroscopic guidance.
- Conditions
- Overactive Bladder, Urinary Incontinence, Fecal Incontinence
- Trial name
- NCT02677753
- Testing
- Fluoroscopy
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University of Louisville
Overactive Bladder, Fecal Incontinence
InterStim Micro Post Market Clinical Follow-up Study (ELITE)
Post-market clinical follow-up for continued assessment of safety and performance to confirm long-term outcomes of the InterStim Micro System for sacral neuromodulation.
- Conditions
- Overactive Bladder, Fecal Incontinence, Non-obstructive Urinary Retention
- Trial name
- ELITE (NCT04506866)
- Testing
- InterStim Micro
- Where
- 24 sites in United States, Canada and 4 more
- Volunteers
- 148 people
- Sponsor
- MedtronicNeuro
Overactive Bladder
A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients
To evaluate the effect of fesoterodine on patient satisfaction and overactive bladder (OAB) symptom relief in OAB patients who were dissatisfied with their prior therapy with tolterodine.
- Trial name
- NCT00425100
- Testing
- fesoterodine fumarate
- Where
- 60 sites in United States, Belgium and 7 more
- Volunteers
- 516 people
- Sponsor
- Pfizer
Overactive Bladder, Urinary Incontinence
The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence
This study aims to assess the efficacy of a specialized herbal formula, Urox, versus control over 8 weeks, in a double blind, placebo controlled trial.
- Conditions
- Overactive Bladder, Urinary Incontinence, Urinary Frequency or Urgency Adverse Event, Nocturia
- Trial name
- NCT02396160
- Testing
- Urox
- Volunteers
- 150 people
- Sponsor
- The University of Queensland
Urinary Incontinence, Urge
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
The purpose of this randomized, open-label, active-control trial is to compare the effectiveness of intra-detrusor botulinum toxin A (Botox A®, Allergan) versus sacral neuromodulation (InterStim®, Medtronic) for the treatment of…
- Trial name
- ROSETTA (NCT01502956)
- Testing
- InterStim® device, Botox® injection
- Where
- 9 sites in United States
- Volunteers
- 386 people
- Sponsor
- NICHD Pelvic Floor Disorders Network
Overactive Bladder, Overactive Bladder Syndrome
OnabotulinumtoxinA Bladder Injection Study
Patients with overactive bladder (OAB) will be randomly assigned (like a flip of a coin) to receive 100 units of onabotulinumtoxinA injected into the bladder at either 3 sites or 10 sites.
- Conditions
- Overactive Bladder, Overactive Bladder Syndrome, Urinary Urgency, Urinary Incontinence
- Trial name
- NCT03523091
- Testing
- OnabotulinumtoxinA 100Unit Injection
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Corewell Health East
Overactive Bladder
Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)
Abstract Introduction: Urgency Urinary Incontinence (UUI) is a common condition with a prevalence of 9-31% in women in the United States.
- Trial name
- PTNS-M (NCT04907032)
- Testing
- Mirabegron 50 MG, Posterior Tibial Nerve Stimulation (PTNS)
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Overactive Bladder, Overactive Bladder Syndrome
Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection
The goal of this clinical trial is to evaluate the outcomes of differing durations of antibiotic prophylaxis with bladder onabotulinumtoxinA injection in patients with refractory overactive bladder.
- Conditions
- Overactive Bladder, Overactive Bladder Syndrome, Urge Incontinence, Urinary Incontinence, Urge
- Trial name
- NCT05719285
- Testing
- Single-Dose Antibiotic, Multi-Dose Antibiotic
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Overactive Bladder
PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
To evaluate the NURO system for the treatment of OAB in drug naïve patients.
- Trial name
- RESET (NCT02857816)
- Testing
- NURO System PTNM Therapy
- Where
- 11 sites in United States
- Volunteers
- 154 people
- Sponsor
- MedtronicNeuro
Overactive Bladder (OAB), Pharmacokinetics of Mirabegron
A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)
The purpose of this study was to evaluate the efficacy of mirabegron in children (5 to < 12 years of age) with OAB. This study will also evaluated the safety and tolerability of mirabegron in pediatric participants with OAB and…
- Trial name
- Dolphin (NCT04641975)
- Testing
- Mirabegron
- Where
- 15 sites in Belgium, France and 8 more
- Volunteers
- 26 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Detrusor Overactivity, Multiple Sclerosis
A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis
The purpose of this study is to evaluate the efficacy of Sativex® compared with placebo in reducing the daily number of episodes on incontinence.
- Trial name
- NCT00678795
- Testing
- Sativex®
- Where
- United Kingdom
- Volunteers
- 135 people
- Sponsor
- Jazz Pharmaceuticals
Parkinson's Disease, Neurogenic Bladder
Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease
The basic nerve deficit of Parkinson's disease (PD) leads to lower urinary tract symptoms of frequency, urgency and urge urinary incontinence. Lower urinary tract symptoms tend to occur at more advanced stages of PD.
- Conditions
- Parkinson's Disease, Neurogenic Bladder, Urinary Incontinence, Clostridium Botulinum Toxin Adverse Reaction
- Trial name
- NCT01421719
- Testing
- Cystoscopic injection of Botox into the urinary bladder
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Overactive Bladder, Lower Urinary Tract Symptoms
Combined Behavioral and Drug Treatment of Overactive Bladder in Men
The primary aim of this project is to evaluate the effectiveness of combined behavioral + drug therapy compared to behavioral treatment alone and drug therapy alone as a way to improve outcomes in the treatment of OAB symptoms in…
- Trial name
- COBALT (NCT01175382)
- Testing
- Behavioral training, Tolterodine + tamsulosin, Combined Behavioral + Drug Therapy
- Where
- 3 sites in United States
- Volunteers
- 204 people
- Sponsor
- University of Alabama at Birmingham
Urinary Bladder Overactive, Overactive Bladder
A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder
The purpose of this study was to examine how well the combination of two medicines (solifenacin succinate and mirabegron) worked compared to each medicine alone in the treatment of bladder problems, and how safe they were for…
- Conditions
- Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence, Urinary Bladder Diseases\Urologic Diseases
- Trial name
- SYNERGY II (NCT02045862)
- Testing
- Solifenacin succinate, Mirabegron
- Where
- 251 sites in United States, Australia and 30 more
- Volunteers
- 1,829 people
- Sponsor
- Astellas Pharma Europe B.V.
Urge Urinary Incontinence, Overactive Bladder
Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)
Six hundred and thirty-six women diagnosed with urge urinary incontinence (UUI) by a three-item self-administered questionnaire (3IQ) will be randomized to 12 weeks of fesoterodine or matching placebo.
- Trial name
- BRIDGES (NCT00862745)
- Testing
- Fesoterodine
- Where
- 13 sites in United States
- Volunteers
- 645 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Urinary Bladder, Overactive
An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants
The objective of this study is to evaluate the efficacy of oxybutynin chloride oral osmotic therapeutic system (OROS) on patient-reported outcomes after 12 weeks of treatment by dose escalation in participants with overactive…
- Trial name
- NCT00613327
- Testing
- Oxybutynin chloride OROS
- Volunteers
- 345 people
- Sponsor
- Janssen Korea, Ltd., Korea